SMARCA1 and Patent ductus arteriosus: These two trials established the relative safety of EZH2 inhibitors in the treatment of solid organ malignancy and, together with stratification based on SWI/SNF mutation status, could form a viable epigenetic treatment approach for patients with PDA.